0 CHECKOUT

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015

  • ID: 2889861
  • November 2015
  • Region: Global
  • 961 Pages
  • CurrentPartnering
1 of 4

The Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2011
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta - Nerviano Medical Sciences - November 2013
3.3.1.b. Case study 2: Sanofi - Pozen - September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure - January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals - September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena - May 2013
3.4.2.b. Case study 6: Abbvie - Receptos - March 2013

Chapter 4 - Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Big pharma licensing deal activity
4.4. Big biotech licensing deal activity

Chapter 5 - Licensing deal term benchmarks

5.1. Introduction
5.1.2. Licensing headline values
5.1.3. Licensing upfront payments
5.1.4. Licensing milestone payments
5.1.5. Licensing royalty rates

Chapter 6 - Big pharma licensing deals

6.1. Introduction
6.2. How to use licensing deals
6.3. Big pharma company licensing agreement listings

Chapter 7 - Big biotech licensing deals

7.1. Introduction
7.2. How to use licensing deals
7.3. Big biotech licensing agreement listings

Chapter 8 - Licensing contract directory 2011-2015

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area

Appendix
Appendix 1 - Resources
Appendix 2 - Deal type definitions
About
Recent report titles

Additonal appendices - see separate PDF documents:
Appendix 1 - Licensing dealmaking - by financial disclosure
Appendix 2 - Licensing dealmaking - by companies A-Z
Appendix 3 - Licensing dealmaking - by stage of development
Appendix 4 - Licensing dealmaking - by therapeutic target
Appendix 5 - Licensing dealmaking - by technology type

Table of Figures:
Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2011-2015
Figure 5: Licensing deals signed at each phase of development, 2011-2015
Figure 6: Licensing deals by therapy area, 2011-2015
Figure 7: Licensing agreements - what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2011 exceeding $1bn
Figure 10: Most active licensing dealmakers 2011-2015
Figure 11: Most active licensing dealmakers 2011-2015 by therapy area
Figure 12: Most active licensing dealmakers 2011-2015 - by stage of development
Figure 13: Big pharma - top 50 - licensing deals 2010 to 2015
Figure 14: Big pharma licensing deal frequency - 2010 to 2015
Figure 15: Big biotech - top 50 - licensing deals 2010 to 2015
Figure 16: Big biotech licensing deal frequency - 2009 to 2015
Figure 17: Licensing deals headline value distribution, US$million - discovery stage
Figure 18: Licensing deals headline value distribution, US$million - preclinical stage
Figure 19: Licensing deals headline value distribution, US$million - phase I stage
Figure 20: Licensing deals headline value distribution, US$million - phase II stage
Figure 21: Licensing deals headline value distribution, US$million - phase III stage
Figure 22: Licensing deals headline value distribution, US$million - regulatory stage
Figure 23: Licensing deals headline value distribution, US$million - marketed stage
Figure 24: Licensing deal upfront payment distribution, US$million - discovery stage
Figure 25: Licensing deal upfront payment distribution, US$million - preclinical stage
Figure 26: Licensing deals upfront value distribution, US$million - phase I stage
Figure 27: Licensing deals upfront value distribution, US$million - phase II stage
Figure 28: Licensing deals upfront value distribution, US$million - phase III stage
Figure 29: Licensing deals upfront value distribution, US$million - regulatory stage
Figure 30: Licensing deals upfront value distribution, US$million - marketed stage
Figure 31: Licensing deal milestone distribution, US$million - discovery stage
Figure 32: Licensing deals milestone distribution, US$million - preclinical stage
Figure 33: Licensing deals milestone distribution, US$million - phase I stage
Figure 34: Licensing deals milestone distribution, US$million - phase II stage
Figure 35: Licensing deals milestone distribution, US$million - phase III stage
Figure 36: Licensing deals milestone distribution, US$million - regulatory stage
Figure 37: Licensing deals milestone distribution, US$million - marketed stage
Figure 38: Licensing deals with royalty rates, %
Figure 39: Licensing deals royalty rate distribution, %- discovery stage
Figure 40: Licensing deals royalty rate distribution, %- preclinical stage
Figure 41: Licensing deals royalty rate distribution, %- phase I stage
Figure 42: Licensing deals royalty rate distribution, %- phase II stage
Figure 43: Licensing deals royalty rate distribution, %- phase III stage
Figure 44: Licensing deals royalty rate distribution, %- regulatory stage
Figure 45: Licensing deals royalty rate distribution, %- marketed stage
Figure 46: Online partnering resources
Figure 47: Deal type definitions

Note: Product cover images may vary from those shown
3 of 4

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 provides the reader with the following key benefits:

- In-depth understanding of licensing partnering deal trends since 2011.
- Insight into the terms included in a licensing agreement, together with real world clause examples.
- Identify leading licensing deals by value since 2011.
- Identify the most active licensing dealmakers since 2011.
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates.
- Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus.
- Comprehensive access to over 3,500 licensing deals entered into by the world’s biopharma companies, together with contract documents if available.
- Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies.
- Understand the key deal terms companies have agreed in previous deals.
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A printed copy of the report and CD ROM copy will be shipped to you.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • bioCSL
  • Abbott Laboratories Ltd.
  • Radiometer Limited
  • Genfit
  • Focus Diagnostics Inc.
  • Genomic Health Inc.